|Articles|November 1, 1999

The Clinical and Economic Impact of Pneumococcal Disease in the Pediatric Population
Volume 5
Issue 17 Suppl

Into the Era of the Pneumococcal Conjugate Vaccine

Author(s)Jerome O. Klein, MD

Download PDF: Into the Era of the Pneumococcal Conjugate Vaccine

Articles in this issue

almost 27 years ago

Article

Participating Faculty

almost 27 years ago

Article

Introduction

almost 27 years ago

Article

Epidemiology of Pneumococcal Disease

almost 27 years ago

Article

The Costs of Antimicrobial Treatment Failure in Acute Otitis Media

almost 27 years ago

Article

Prevention of Pneumococcal Disease in High-Risk Pediatric Groups

almost 27 years ago

Article

The Clinical Impact of Pneumococcal Conjugate Vaccines

almost 27 years ago

Article

Economic Impact of Pneumococcal Conjugate Vaccine in Managed Care

almost 27 years ago

Article

Selected Abstracts

almost 27 years ago

Article

CME Quiz

almost 27 years ago

Article

Bibliography

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Into the Era of the Pneumococcal Conjugate Vaccine

Articles in this issue

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care

Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%

Study Shows Potential for Low-Dose CAR T, With Implications for Increased Access

FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies